Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Shanghai MicroPort MedBot / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-microport-medbot-group-co-ltd" target="_blank" data-smartkarma-citation="entities:33485:1" rel="noopener">Shanghai MicroPort MedBot Group (2252 HK)</a> recorded revenue of RMB 551.1M for 2025, representing an increase of 114%, and net loss narrowed down narrowed down to RMB 254M in 2025.</li>
<li>Company achieved a milestone breakthrough in commercialisation in overseas markets, recording overseas sales revenue of RMB 400.2M (73% of total revenue), representing a significant increase of 287% YoY.</li>
<li>Approvals of Toumai variants and other products, technology advantages and commercialisation strength has helped the company’s growth momentum to gain pace and eventually it will bring it back to black.</li>
</ul>



Shanghai MicroPort MedBot Group (2252 HK) recorded revenue of RMB 551.1M for 2025, representing an increase of 114%, and net loss narrowed down narrowed down to RMB 254M in 2025.
Company achieved a milestone breakthrough in commercialisation in overseas markets, recording overseas sales revenue of RMB 400.2M (73% of total revenue), representing a significant increase of 287% YoY.
Approvals of Toumai variants and other products, technology advantages and commercialisation strength has helped the company’s growth momentum to gain pace and eventually it will bring it back to black.


MicroPort MedBot (2252 HK): Toumai Grew by Leaps and Bounds in 2025, Momentum to Sustain Going Ahead

Thematic (Sector/Industry)

<ul>
<li>CSPC Pharmaceutical’s SYS6010 met primary endpoint in Phase 3 study as a monotherapy for NSCLC. Akeso’s ivonescimab demonstrates significant overall survival in Phase 3 trial for advanced biliary tract cancer.</li>
<li>Takeda Pharma secured FDA approval for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. Astellas Pharma initiates global Phase 3 study evaluating ASP2138 for gastric cancers.</li>
<li>Hanmi Pharm outlicenses obesity drug candidate HM1732 to Genentech for a total deal value of $2.3B. SK Biopharmaceuticals entered an agreement to in-license opakalim, an investigational antiseizure medication, from Biohaven.</li>
</ul>


CSPC Pharmaceutical’s SYS6010 met primary endpoint in Phase 3 study as a monotherapy for NSCLC. Akeso’s ivonescimab demonstrates significant overall survival in Phase 3 trial for advanced biliary tract cancer.
Takeda Pharma secured FDA approval for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. Astellas Pharma initiates global Phase 3 study evaluating ASP2138 for gastric cancers.
Hanmi Pharm outlicenses obesity drug candidate HM1732 to Genentech for a total deal value of $2.3B. SK Biopharmaceuticals entered an agreement to in-license opakalim, an investigational antiseizure medication, from Biohaven.


APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

<ul>
<li>Henlius Biotech is collaborating with Sandoz for commercialization of up to 10 biosimilars in ~$322M deal. Wuxi XDC achieved GMP release of its antibody bioconjugates production line at Singapore site.</li>
<li>Chugai Pharmaceutical signed an exclusive license agreement with GSK for the anti-dengue virus antibody AID351. Daiichi Sankyo’s Enhertu demonstrated PFS improvement as first-line treatment of NSCLC in Phase 3 trial.</li>
<li>Celltrion has launched IV formulation of Steqeyma in Japan. Eubiologics submitted an IND to the MFDS for domestic Phase 1 trial for its Alzheimer’s disease vaccine candidate, Padivax.</li>
</ul>


Henlius Biotech is collaborating with Sandoz for commercialization of up to 10 biosimilars in ~$322M deal. Wuxi XDC achieved GMP release of its antibody bioconjugates production line at Singapore site.
Chugai Pharmaceutical signed an exclusive license agreement with GSK for the anti-dengue virus antibody AID351. Daiichi Sankyo’s Enhertu demonstrated PFS improvement as first-line treatment of NSCLC in Phase 3 trial.
Celltrion has launched IV formulation of Steqeyma in Japan. Eubiologics submitted an IND to the MFDS for domestic Phase 1 trial for its Alzheimer’s disease vaccine candidate, Padivax.


APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-microport-medbot-group-co-ltd" target="_blank" data-smartkarma-citation="entities:33485:1" rel="noopener">Shanghai MicroPort MedBot Group (2252 HK)</a> received the approval of the group’s self-developed bronchoscopic surgical robot UniPath Electronic Bronchoscopic Surgical Robotic System from NMPA.</li>
<li>The already existing approved bronchoscopic surgical robotic system in China are Ion Surgical System by Intuitive Surgical, MONARCH Bronchoscope by J&amp;J MedTech and Edge Medical's Edge CP1000.</li>
<li>The recent approvals for the companies Toumai products and now the Unipath Bronchoscopic system will help further gain sales momentum eventually bringing the company on the brink of profit.</li>
</ul>



Shanghai MicroPort MedBot Group (2252 HK) received the approval of the group’s self-developed bronchoscopic surgical robot UniPath Electronic Bronchoscopic Surgical Robotic System from NMPA.
The already existing approved bronchoscopic surgical robotic system in China are Ion Surgical System by Intuitive Surgical, MONARCH Bronchoscope by J&amp;J MedTech and Edge Medical's Edge CP1000.
The recent approvals for the companies Toumai products and now the Unipath Bronchoscopic system will help further gain sales momentum eventually bringing the company on the brink of profit.


MicroPort MedBot (2252 HK): UniPath Bronchoscopic System Approval Will Add To The Growth Momentum

<ul>
<li>Fosun Pharmaceutical initiated Phase 2 trial of FXS7553 for COPD in China. CSPC Pharma’s mpox mRNA vaccine candidate obtained clinical trial approval from the FDA.</li>
<li>Akeso secured NMPA approval for ivonescimab, in combination with chemotherapy, for the treatment of first-line squamous non-small cell lung cancer (sq-NSCLC). This indication marks ivonescimab’s third major approval.</li>
<li>Daiichi Sankyo’s Enhertu got China approval for the first-line treatment of breast cancer. Peptidream marked a milestone following the initiation of Phase 1 study for two radioligand therapies by Novartis.</li>
</ul>


Fosun Pharmaceutical initiated Phase 2 trial of FXS7553 for COPD in China. CSPC Pharma’s mpox mRNA vaccine candidate obtained clinical trial approval from the FDA.
Akeso secured NMPA approval for ivonescimab, in combination with chemotherapy, for the treatment of first-line squamous non-small cell lung cancer (sq-NSCLC). This indication marks ivonescimab’s third major approval.
Daiichi Sankyo’s Enhertu got China approval for the first-line treatment of breast cancer. Peptidream marked a milestone following the initiation of Phase 1 study for two radioligand therapies by Novartis.


APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

China

Shanghai MicroPort MedBot is a surgical robot company that designs, develops, manufactures, and commercializes surgical robots and associated digital surgical solutions. Its product portfolio covers surgical specialties including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture, with key products like the Toumai laparoscopic surgical robot, DFVision 3D electronic laparoscope, and SkyWalker orthopedic surgical robot. The company is headquartered in Shanghai, China, and was officially established in 2015.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai MicroPort MedBot (2252 HK)

MicroPort MedBot (2252 HK): Toumai Grew by Leaps and Bounds in 2025, Momentum to Sustain Going Ahead

Shanghai MicroPort MedBot (2252 HK) sees revenue soar in 2025, with Toumai overseas sales driving growth. Losses narrow. Growth momentum will gain...

Tina Banerjee

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Tina Banerjee

APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion

Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....

Tina Banerjee

MicroPort MedBot (2252 HK): UniPath Bronchoscopic System Approval Will Add To The Growth Momentum

MicroPort MedBot management expects the 2025 revenue of the company will achieve a growth of approximately 110%-120% YoY, mainly attributable to...

Tina Banerjee

APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

MicroPort MedBot (2252 HK): Toumai Grew by Leaps and Bounds in 2025, Momentum to Sustain Going Ahead

​Shanghai MicroPort MedBot (2252 HK) sees revenue soar in 2025, with Toumai overseas sales driving growth. Losses narrow. Growth momentum will gain...

Tina Banerjee

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Tina Banerjee

APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion

Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....

Tina Banerjee

MicroPort MedBot (2252 HK): UniPath Bronchoscopic System Approval Will Add To The Growth Momentum

MicroPort MedBot management expects the 2025 revenue of the company will achieve a growth of approximately 110%-120% YoY, mainly attributable to...

Tina Banerjee

APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...

Tina Banerjee

Shanghai MicroPort MedBot (2252 HK) sees revenue soar in 2025, with Toumai overseas sales driving growth. Losses narrow. Growth momentum will gain...